Interim analysis findings showed the perioperative treatment group demonstrated a statistically significant improvement in event-free survival compared with adjuvant radiotherapy, with or without ...

Esophageal cancer occurring in patients with head and neck squamous cell carcinoma (HNSCC) represents a critical clinical challenge, as these secondary tumours notably worsen patient prognosis. Owing ...

Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer Newly diagnosed patients with cT2-4N0-2M0 HNC were ...

Panelists discuss how recurrent metastatic head and neck squamous cell carcinoma (HNSCC) manifests through symptoms such as persistent sore throat and neck lumps, with risk factors including tobacco ...

Adding neoadjuvant and adjuvant pembrolizumab to the standard of care significantly improved event-free survival in patients with previously untreated, locally advanced head and neck squamous cell ...

Characterization of dynamic changes in tumor-infiltrating lymphocytes (TIL) after neoadjuvant administration of CUE-101, an HPV16 E7-HLA-IL2 fusion protein, to patients with HPV+ locally advanced ...

Keytruda and Efti combination therapy achieved a median overall survival of 17.6 months in head and neck squamous cell carcinoma with PD-L1 CPS less than one. The combination therapy demonstrated a ...

Schematic representation depicts the mechanism by which the ENO2-derived oncometabolite PEP directly binds to HDAC1 and thereby promotes H3K18la, which promotes macrophage polarization and leads to ...

In a national cohort study of patients with resectable head and neck squamous cell carcinoma (HNSCC), the number receiving neoadjuvant immunotherapy began to rise markedly in 2013, while use of ...

Genetic ancestry plays a key role in determining the behavior of head and neck tumors and may help explain why ...